Efficacy, safety of biosimilar filgrastim similar to that of filgrastim in daily practice
the ONA take:
The clinical effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim for the prevention of chemotherapy-induced (febrile) neutropenia, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the international, prospective, observational, open-label MONITOR-GCSF study, researchers enrolled 1,447 patients with cancer treated with myelosuppressive chemotherapy and receiving prophylaxis with biosimilar filgrastim. Of those, 72.3% received primary prophylaxis and 53.2% initiated prophylaxis between 24 and 72 hours after chemotherapy.
Results showed that 13.2% and 5.9% of patients experienced grade 4 chemotherapy-induced neutropenia and febrile neutropenia, respectively.
Researchers found that 6.1% of patients were hospitalized for (febrile) neutropenia. In regard to safety, 24.7% of patients reported any grade bone pain and 76 patients experienced a total of 148 adverse drug events, of which 4 were serious.
Effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|